The effect of ceramide-containing skin care products on eczema resolution duration.
Eczema is a common dermatologic condition that affects children as well as adults and is related to a defective skin barrier, which is most commonly caused by damage to the intercellular lipids from improper selection of skin cleansers and moisturizers. A new concept in skin care is the incorporation of ceramides into therapeutic cleansers and moisturizers. Ceramides are important components of the intercellular lipids that are necessary to link the protein-rich corneocytes into a waterproof barrier that is capable of protecting the underlying skin tissues and regulating body homeostasis. This study evaluated the effect of both a multilamellar vesicular emulsion (MVE) ceramide-containing liquid cleanser and moisturizing cream plus fluocinonide cream 0.05% compared with a bar cleanser plus fluocinonide cream 0.05% in the treatment of mild to moderate eczema. The addition of an MVE ceramide-containing liquid cleanser and moisturizing cream to a high-potency corticosteroid enhanced the treatment outcome of mild to moderate eczema compared with the use of a bar cleanser and high-potency corticosteroid in reducing disease duration, time to disease clearance, and symptoms. Thus, skin care product selection can have an important clinical effect on the clearance of mild to moderate eczema.
Draelos
Zoe Diana
ZD
Dermatology Consulting Services, High Point, North Carolina, USA. zdraelos@northstate.net
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002518:Ceramides / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004485:Eczema / Q000188:drug therapy* / Q000473:pathology; D004643:Emollients / Q000008:administration & dosage*; D004655:Emulsions; D005447:Fluocinonide / Q000008:administration & dosage*; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged; D012720:Severity of Illness Index; D016037:Single-Blind Method; D012867:Skin / Q000473:pathology; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D002518:Ceramides; D003879:Dermatologic Agents; D004643:Emollients; D004655:Emulsions; D005938:Glucocorticoids; D005447:Fluocinonide